Medical Doctor Program year 2024 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Salim Wehbe

Urogynecology and Reconstructive Pelvic Surgery Sacramento, CA Medical Doctor

NPI 1699714626 CMS profile 212726

4860 Y St Ste 2500, Ambulatory Care Center, Ob/Gyn Clinic, Uc Davis, Sacramento, CA 95817

Open in the dashboard

General payments

$262

3 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$80,000

4 holdings reported · through program year 2024

Through program year 2024, Salim Wehbe of Sacramento, CA is reported in the CMS Open Payments database as having received $262 across 3 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $80,000 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 9th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $80 1
2023 General $146 1
2021 General $36 1
2025 Ownership $20,000 1
2024 Ownership $20,000 1
2023 Ownership $20,000 1
2022 Ownership $20,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Salim Wehbe
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Salim Wehbe were reported at $0. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Salim Wehbe Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $0 $358 $132–$1,270 $163
2020 $0 $198 $86–$642 $114
2021 $36 $361 $118–$1,182 $132
2022 $0 $410 $128–$1,175 $149
2023 $146 $434 $152–$1,344 $160
2024 $80 $494 $193–$1,331 $164
2025 $0 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Boston Scientific Corporation $262 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $262 3 payments
Products named General payments · program years 2021–2024
  1. Advantage System $146 1 payment
  2. Solyx SIS System $80 1 payment
  3. SOLYX $36 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,385

Median for Undefined Physician type: 319

Drug cost

$150,232

Median for Undefined Physician type: $28,032

Branded share of claims

31.1%

Median for Undefined Physician type: 24.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 98 $67,374
Yuvafem Estradiol Brand 208 $20,562
Estradiol Generic 342 $15,898
Mirabegron Er Mirabegron Brand 35 $13,815
Trospium Chloride Generic 197 $12,247
Estring Estradiol Brand 16 $9,788
Methenamine Hippurate Generic 82 $4,844
Solifenacin Succinate Generic 57 $1,545
Cephalexin Generic 106 $1,221
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 56 $651

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 138 Part D prescribers listed as Undefined Physician type; they describe a distribution and say nothing about conduct.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record